On this page
Quick answer
Some medicines acting on can help treat obesity by regulating appetite and increasing fullness. They are used with a medical indication, nutrition and physical activity. Benefits, risks and duration need an individual assessment.
Educational information for adults. This is not a prescription or an individual medical assessment. Longevity Online is a wellbeing plan: it does not include medicines or obesity treatment. GLP‑1 use requires a medical indication, prescription and healthcare follow-up.
Medical terms, explained
Hover, use keyboard focus or tap an underlined word to see its meaning.
Read all definitions
- GLP-1
- Glucagon-like peptide-1: a gut hormone involved in insulin release after eating and appetite regulation. Source
- GIP
- Glucose-dependent insulinotropic polypeptide: a gut hormone that helps release insulin in response to food. Source
- BMI
- Body mass index: weight in kilograms divided by height in metres squared. An indicative measure, not a measure of body composition. Source
- Waist/height
- Waist circumference divided by height in the same units. Helps assess central adiposity alongside BMI; it is not a diagnosis. Source
What do we mean by obesity?
WHO describes obesity as a chronic disease influenced by biology, environments, social conditions and behaviour. Reducing it to a lack of willpower makes it harder to understand and treat.
In adults, a body mass index of 30 or above is used as a threshold for obesity. alone does not describe body composition or a person's health: assessment also considers complications, function and context.
How do GLP‑1 medicines work?
is a hormone involved in the response to food. Medicines activating its receptor affect fullness and appetite and help regulate glucose. Semaglutide is a receptor agonist. Tirzepatide acts on both and receptors; it is not a pure agonist.
Indications depend on the medicine and its authorisation. A medicine authorised for diabetes should not automatically be described as authorised for obesity.
Where do they fit in obesity care?
WHO's December 2025 guideline makes conditional recommendations for long-term use of these therapies in adults with obesity, excluding pregnant women. It places them alongside comprehensive care, healthy behaviours and professional support.
The recommendation is conditional because of long-term evidence, continuity, cost and access issues. This page does not determine whether a medicine is suitable for you or open a prescribing service at Innova Longevity.
BMI and waist-to-height ratio
An indicative tool for adults aged at least 18 who are not pregnant. Enter height and weight; waist measurement is optional. All length measurements must be in centimetres (cm).
Calculated on this device. These measurements are not saved or sent anywhere.
These results are neither a diagnosis nor a probability of disease. No number alone indicates treatment with GLP-1 or any other medicine; decisions require clinical assessment.
How to read these numbers
This tool excludes people under 18 and pregnant people. BMI does not distinguish fat from muscle: high muscle mass can affect its interpretation. For adults over 65, function, nutritional status and other circumstances must be considered. Clinical context and ethnic background also matter: no universal BMI classification is applied here to everyone.
NICE NG246 uses waist-to-height ratio alongside BMI in adults with BMI <35. Its bands are a central adiposity reference, not an assessment of overall health.
Technical validation limits: height 100–250 cm, weight 20–400 kg and waist 30–250 cm. These are not clinical cut-offs and do not define what is healthy; consult a professional if your measurements fall outside them.
Source: NICE NG246 · recommendations 1.9.5, 1.9.8, 1.9.14 and 1.9.15 (Opens in a new tab)
2025 guideline · checked on 10 November 2026.
Frequently asked questions
Are GLP‑1 medicines for cosmetic weight loss?
EMA warns against purely cosmetic weight loss use in people without obesity or with overweight without related health conditions. These medicines require a prescription and medical supervision.
Are tirzepatide and semaglutide the same?
No. Semaglutide activates receptors; tirzepatide activates and receptors. They have specific authorisations and evidence and should not be substituted without a prescriber.
Does Longevity Online include GLP‑1 medicines?
No. Longevity Online organises nutrition, movement and wellbeing habits. It does not include medicines, prescriptions or medical obesity treatment.
Original sources
Source publication date or date regulatory information was checked.
- WHO · Obesity and overweight(Opens in a new tab)
2026-10-07
https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
- WHO · Global guideline on GLP-1 medicines and obesity(Opens in a new tab)
2025-12-01
https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
- EMA · Appropriate use of GLP-1 receptor agonists(Opens in a new tab)
2024-06-26
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists
- EMA · regulatory information on GLP-1 medicines(Opens in a new tab)
Información regulatoria consultada
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists
- EMA · regulatory information on GLP-1 medicines(Opens in a new tab)
Información regulatoria consultada
https://www.ema.europa.eu/en/news/eu-actions-tackle-shortages-glp-1-receptor-agonists